John Maraganore joins up with Pro­QR as strate­gic ad­vi­sor; Servi­er nabs pri­or­i­ty re­view for Tib­so­vo sN­DA

Af­ter a month-long break from ad­vi­so­ry ap­point­ments, John Maraganore is once again be­ing tapped to join an­oth­er biotech.

The RNA-fo­cused start­up an­nounced Maraganore’s ap­point­ment this morn­ing, with the Al­ny­lam found­ing CEO join­ing up as a strate­gic ad­vi­sor to Pro­QR’s su­per­vi­so­ry board.

Mon­day’s move comes a few weeks af­ter the biotech’s lead can­di­date for the rare ge­net­ic eye dis­ease, Leber con­gen­i­tal amau­ro­sis, had shown no dif­fer­ence be­tween place­bo and any oth­er ef­fi­ca­cy mea­sures. Maraganore said in a state­ment that he first met Pro­QR CEO Daniel de Boer more than a decade ago through for­mer Gen­zyme CEO Hen­ri Ter­meer, be­fore his pass­ing in 2017.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.